Eleven Biotherapeutics, Cambridge, MA

Eleven Biotherapeutics

www.elevenbio.com

"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."

More>>

Number of Employees: 0-25
Annual Revenue: $1-10 Million

www.elevenbio.com
215 First Street Suite 400
Cambridge, MA USA 02142
Phone: 617.871.9911

Similar Companies

Buoy Health

Buoy is a Boston-based digital health company that uses AI technology to provide personalized clinical support the moment an individual has a health concern. Developed out of the Harvard Innovation Labs by a team of doctors and data scientists, Buoy navigates people through the healthcare system intelligently, delivering triage at scale, and connecting them with the right care endpoints at the right time based on self-reported symptoms.

Central Georgia Health Network

CGHN has been a trusted partner for Central Georgia independent physicians for over 20 years, with proven success in favorable payouts, dividends and contracting. This commitment to physician independence is at the very heart of CGHN`s identity. CGHN`s ownership structure ensures independent physicians in Central Georgia maintain a strong, controlling governance voice. CGHN is a growing, clinically-integrated network representing nearly 1,000 independent physicians, healthcare professionals and hospital partners across Central Georgia. Our goal is to deliver the best patient care experiences, while enhancing care quality and lowering costs.

Hilltop Village-a Retirement

Hilltop Village-a Retirement is a Euclid, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Consultant People

Consultant People, LP is a Lewisville, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lodi Health

Lodi Memorial Hospital is a general medical and surgical hospital in Lodi, CA, with 214 beds. Survey data for the latest year available shows that 31,080 patients visited the hospital's emergency room. The hospital had a total of 7,139 admissions. Its physicians performed 2,124 inpatient and 2,140 outpatient surgeries.

CTOs on the Move